About this trial
1. Study the immunohistochemical expression of ALDOA in bladder urothelial cancer. 2. Correlate between ALDOA expression in specimens and different cilnicopathological factors. 3. Correlate between ALDOA expression and urothelial cancer prognosis and survival.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All cases diagnosed as bladder urothelial cancer with known follow-up data and presence of muscle proper detected in the specimens.
Disqualifiers
Subtypes of bladder cancer other than urothelial carcinoma subtype.
Cases of urothelial carcinoma without known follow up data.
Cases of urothelial carcinoma without muscle proper detected in the specimen.
Trial population
The study will be conducted using formalin fixed paraffin embedded blocks of fifty cases of urothelial carcinomas . These blocks will be obtained from laboratory archives of the Pathology Department, Assiut University Hospital, Faculty of Medicine. Clinical data for this study will be obtained from laboratory archives of the pathology department, Assiut University Hospital, Assiut University.
Trial design
Case-control
Retrospective
Treatments tested in this trial
Immunohistochemistry
GeneticImmunohistochemical expression of ALDOA in bladder urothelial carcinoma
Treatment groups
Trial outcomes
Primary outcomes
Evaluate the immunohistochemical expression of ALDOA in bladder urothelial carcinoma.
Microscopic examination of bladder urothelial carcinoma spicemens and staining them with ALDOA marker
Secondary outcomes
Evaluate relation between ALDOA expression and cilnicopathological features and patient survival.
Correlate between ALDOA expression and the different clinicopathological factors of patients and their survival.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: